Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective Registry for the Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intravenous Injection in Patients With Paroxysmal and Persistent Atrial Fibrillation and Flutter

NCT05773170 is registered in ClinicalTrials.gov with R-Pharm as lead sponsor.

NCT NCT05773170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05773170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective Registry for the Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intravenous Injection in Patients With Paroxysmal and Persistent Atrial Fibrillation and Flutter
Lead sponsor
R-Pharm
Phase
Observational
Overall status
Completed
Start date
November 11, 2022
Completion date
June 1, 2023
Enrollment
1,147 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

atrial flutter, paroxysmal atrial fibrillation, persistent atrial fibrillation